A spokesperson for GlaxoSmithKline told reporters that the company will make an announcement to US employees tomorrow about a reorganization, prompting press speculation about cuts to US-based sales forces.
Genzyme and Osiris Therapeutics have announced a partnership to develop and commercialize Prochymal and Chondrogen, two late-stage adult stem cell treatments. Osiris will commercialize the two treatments in the US and Canada, with Genzyme marketing the treatments in other countries.
